European Commission (EC) approves brolucizumab injection for the treatment of wet age-related macular degeneration (AMD)

The approval is based on findings from the phase III HAWK and HARRIER clinical trials, in which brolucizumab met the primary endpoint demonstrating gains in best corrected visual acuity that were non-inferior to aflibercept at year one.

SPS commentary:

Brolucizumab is a humanised monoclonal single chain FV antibody fragment targeting vascular endothelial growth factor (VEGF) - it inhibits VEGF-A.